daylette 0.02mg/3mg tablets
consilient health ltd - drospirenone; ethinylestradiol - oral tablet - 3mg ; 20microgram
daylette 3 mg/ 0,02 mg comprimidos recubiertos con pelicula efg , 28 comprimidos
daylette 3 mg/ 0,02 mg comprimidos recubiertos con pelicula efg , 84 (3 x 28) compri
daylette 0,02 mg - 3 mg film-coat. tabl.
gedeon richter plc - drospirenone 3 mg (white tablet); ethinylestradiol 0,02 mg (white tablet); placebo (green tablet) - film-coated tablet - 0,02 mg - 3 mg - drospirenone 3 mg; ethinylestradiol 0.02 mg; placebo - drospirenone and ethinylestradiol
daylette 0,02 mg/3 mg filmtabletten
valette ethinyloestradiol / dienogest tablet blister pack
bayer australia ltd - dienogest, quantity: 2 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: calcium carbonate; ferric oxide; macrogol 6000; glycol montanate; glycerol; sucrose; lactose monohydrate; maize starch; povidone; titanium dioxide; purified talc; magnesium stearate - valette is indicated for use as an oral contraceptive and in the treatment of mild to moderate acne in women who seek oral contraception.
valette
bayer australia ltd - ethinyloestradiol; dienogest -
palette life sciences deflux gel for injection
transmedic pte ltd - gastroenterology & urology - intended for submucosal injections in the urethra, urinary bladder and distal ureter. indication for use (1) vesicoureteral reflux (2) stress urinary incontinence due to urethral sphincter incompetence. deflux may also be effective for stress urinary incontinence due to urethral hypermobility
palette deflux metal needle
transmedic pte ltd - gastroenterology & urology - intended for submucous injection of deflux® gel in the urinary tract.
barrigel - radiotherapy protection spacer
palette life sciences australia pty ltd - 60424 - radiotherapy protection spacer - barrigel is a sterile, transparent, biodegradable gel of stabilized hyaluronic acid of non-animal origin, supplied in a glass syringe. barrigel acts by adding volume to the tissue, thereby mechanically creating an increased distance between the prostate and the anterior rectal wall. the product degrades over time. barrigel is used to increase the distance between the prostate and the anterior rectal wall, with the intent to decrease radiation dose delivered to the rectum when treating prostate cancer with radiation.